Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir in high-risk adult outpatients with RSV
NCT04978337Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of rilematovir in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Started Nov 2021; status: terminated.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04978337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978337.